HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

New treatments, new outcomes for refractory thyroid cancer


Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?


Potholes on the road to improved cancer outcomes

John Sweetenham, MD

Advanced Practice

Integrating transition from pediatric- to adult-centered care: The APP’s role

Anne Nord, MSN, RN, FNP-C; Deborah G. Harris, MN, RN, CPNP-AC/PC, CPHON®; Susan M. Carson, MSN, RN, CPNP-PC; Trish Peterson, MSN, RN, CPNP-PC

Molecular Oncology

Mind the gap: Precision medicine shortcomings in NSCLC

Howard (Jack) West, MD

Meeting News

Enfortumab vedotin induces responses in advanced urothelial cancer

Asparaginase discontinuation linked to inferior EFS in acute lymphoblastic leukemia

Bispecific T-cell engager AMG 420 active, safe in heavily pretreated multiple myeloma

Broader inclusion criteria could double the number of patients with lung cancer eligible for clinical trials

Concurrent rituximab with cladribine enhances complete responses in untreated hairy cell leukemia

CPX-351 regimen induces high response rates in pediatric relapsed acute myeloid leukemia

Pembrolizumab for advanced hepatocellular carcinoma reduces mortality risk in 'technically ... negative study'

Point-of-care bispecific targeting ‘offers new paradigm’ for CAR T-cell therapy

SurVaxM vaccine appears ‘very promising’ for newly diagnosed glioblastoma

Ribociclib plus endocrine therapy improves survival in advanced breast cancer subtype

Rivaroxaban reduces VTE among ambulatory patients with pancreatic cancer

In the Journals

Oropharynx cancer burden shifting to older individuals

Strategies to identify sickle cell disease among refugees could reduce complications, costs

Machine learning framework ‘much-needed advancement’ in prostate cancer risk assessment

FDA News

FDA approves Jakafi for acute graft-versus-host disease

FDA approves Kanjinti, biosimilar to Herceptin

FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome

Dana-Farber/Boston Children’s named nation’s best hospital for pediatric cancer